North America Injection Pen Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Disposable Injection Pens and Reusable Injection Pens), Therapy (Diabetes, Growth Hormone Therapy, Autoimmune Diseases, Fertility, Cancer, and Others Th

North America Injection Pen Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Disposable Injection Pens and Reusable Injection Pens), Therapy (Diabetes, Growth Hormone Therapy, Autoimmune Diseases, Fertility, Cancer, and Others Therapy), and End User (Hospitals and Clinics, Home Care, and Others)

The North America injection pen market is expected to grow from US$ 13,156.60 million in 2022 to US$ 20,075.51 million by 2028. It is estimated to register a CAGR of 7.3% from 2022 to 2028.

Increase in Strategic Developments in North America Injection Pen Market

The injection pen market is characterized by the presence of various market players. To increase their market share, market players take up various strategies such as product launches, regional expansion, and technological advancements. Injection pens are more involved in continuous innovation and technological advances, leading to increased acceptance among industry players. Leading players invest in R&D to develop advanced technologies and gain more revenue.

A few recent developments related to injection pen are mentioned below:

In May 2022, FDA approved Lilly's Mounjaro injection, the first and only glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes in adults. Mounjaro is available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) and comes in Lilly's well-established auto-injector pen with a pre-attached, hidden needle.

In January 2022, SHL Medical’s partnered with Innovation Zed for connected pen injector solutions. It launched InsulCheck DOSE, a connected add-on device that transforms traditional pen injectors into smart solutions to support the monitoring of disease management regimen.

In May 2021, Lilly collaborated internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes. The company signed strategic international agreements with four companies—DexCom, Inc.; Glooko Inc.; myDiabby Healthcare; and Roche—to advance connected solutions and streamline care for people suffering from diabetes.

All the above-mentioned recent developments are driving the North America injection pen market.

North America Injection Pen Market Overview

The North America injection pen market is segmented into the US, Canada, and Mexico. The market growth in this region is attributed to the increasing incidence of diabetes and infertility and the rising product development in the market. According to the American Diabetes Association, the number of people with diabetes in the US population reached 37.3 million (11.3% of the population) in 2019. Nearly 1.9 million of the US population has type 1 diabetes, including ~244,000 children and adolescents. Further, ~1.4 million diabetes cases are diagnosed each year in the US. According to the Centers for Disease Control and Prevention, in 2020, ~88 million adults had prediabetes, which is 34.5% of the US adult population. According to Yale researchers, in 2022, ~30 million of the US population had diabetes, and about 7 million required daily insulin.

There is an increase in demand for infertility treatment in the US. For instance, according to the CDC, in 2019, in the US, 9% of men and 10% of women aged 15 to 44 reported infertility problems.

North America Injection Pen Market Revenue and Forecast to 2028 (US$ Million)

North America Injection Pen Market Segmentation

The North America injection pen market is segmented on the basis of type, therapy, end user, and country. Based on type, the injection pen market is segmented into disposable injection pens and reusable injection pens. The disposable injection pens segment registered a larger market share in 2022.

Based on therapy, the North America injection pen market is segmented into diabetes therapy, growth hormone therapy, autoimmune diseases therapy, fertility therapy, cancer therapy, and others . The diabetes therapy segment registered the largest market share in 2022.

Based on end user, the North America injection pen market is segmented into hospitals & clinics , home care, and others. The home care segment registered the largest market share in 2022.

Based on country, the North America injection pen market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022.

AstraZeneca Plc, Becton Dickinson and Co, Eli Lilly and Co, Gerresheimer AG, Haselmeier GmbH, Merck KGaA, Novo Nordisk AS, Owen Mumford Ltd, Sanofi SA, and Teva Pharmaceutical Industries Ltd are among the leading companies operating in the North America injection pen market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America injection pen market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the North America injection pen market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the injection pen market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution